The DOI matches its Crossref record.
Sirolimus‐induced hyperlipidaemia in liver transplant recipients is not dose‐dependent
Abstract
Summary: Background : Sirolimus is a potent immunosuppressive medication that acts by inhibiting T‐cell proliferation. It has been used in kidney transplantation because of its lack of nephrotoxicity. It is now being investigated in liver transplantation, but there are concerns about safety and long‐term side effects such as dyslipidaemia. Hypertriglyceridaemia is a common adverse event seen with sirolimus use, and often does not respond to dose reduction or anti‐lipemic drugs. Method : We report six patients who have developed significant hyperlipidaemia while receiving sirolimus, in spite of therapeutic trough levels. Conclusion : All six patients showed either resolution or improvement in lipid levels with discontinuation of sirolimus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chronic treatment of humans with high doses of rapalogs is also associated with deleterious metabolic consequences including hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, insulin resistance and glucose intolerance 139–143.”
From Targeting the biology of aging with mTOR inhibitors (2023) · cites this paper as [142]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 18
- Vazquez EM., 2000, Sirolimus: a new agent for prevention of renal allograft rejection, Am J Health-Syst Pharm, 57, 437, 10.1093/ajhp/57.5.437 · DOI
- 10.1053/jlts.2001.24645 · DOI
- 10.1053/jlts.2000.19023 · DOI
- 10.1126/science.1380182 · DOI
- 10.1016/S0041-1345(96)00008-5 · DOI
- 10.1038/ki.1996.28 · DOI
- 10.1097/00007890-200101270-00019 · DOI
- 10.1053/jlts.2001.23916 · DOI
- 10.1097/00007890-199902270-00002 · DOI
- 10.1053/jlts.2001.26510 · DOI
- 10.1053/jlts.2001.23012 · DOI
- 10.1016/S0041-1345(98)01301-3 · DOI
- 10.1016/S0149-2918(00)89026-8 · DOI
- 10.1097/00007890-199810270-00013 · DOI
- 10.1016/S0041-1345(00)01884-4 · DOI
- 10.1097/00007890-200110150-00011 · DOI
- Wilson JD, 1998, Textbook of Endocrinology, 1103
- Witzum JL, Textbook of Medicine 2000, 1090
Cited by
Sorted by citations
Targeting the biology of aging with mTOR inhibitors
Mannick, J. B., & Lamming, D. W. (2023) · Nature Aging · doi:10.1038/s43587-023-00416-y · Cited by 372
Metadata
- Authors
- Firpi, R. J., Tran, T. T., Flores, P., Nissen, N., Colquhoun, S., Shackleton, C., Martin, P., Vierling, J. M., & Poordad, F. F.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2004-04-08
- Volume
- 19
- Issue
- 9
- Pages
- 1033-1039
- ISSN
- 0269-2813
- 1365-2036
- Cited by
- 28
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
